NeuroVive Pharmaceutical AB announced that Gregory Batcheller resigned as Chair of the company’s board effective midnight November 6, 2017. Following Mr. Batcheller's resignation, the remaining four members of the Board of NeuroVive, unanimously elected sitting Board member, David Laskow-Pooley, as Chair. Mr. Laskow-Pooley will complete the term as Chair through the annual general shareholder meeting in April 26, 2018, when the Board is reconstituted on an annual basis. David is independent from Management. Mr. Laskow-Pooley has been on the NeuroVive Board since 2016. He serves on the Boards of one American and two British companies. David has previous multiyear experience as Chair of the Board at several British companies. David has worked at large pharma including GlaxoSmithKline, Abbot, and Amersham, as well as smaller biotechnology companies. Mr. Laskow-Pooley has special expertise in bringing radiation oncology treatments to market. His roles have spanned corporate fund raising, strategic positioning, discovery, manufacture and sale of pharmaceutical products, diagnostics and devices.